Amedisys (AMED) Misses Q4 EPS by 10c, Beats on Revenue

Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.96, $0.10 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $598.1 million versus the consensus estimate of $596.76 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Morgan Stanley Resumes OMV AG (OMV:AV) (OMVKY) at Equalweight
• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold